Life Science Partner recruits former Oncology Regulatory Officer for Johnson & Johnson, Pharmaceutical and Research & Development.
Life Science Partner announces the recruitment of Steve Hamburger, a global regulatory and drug development executive, to Exoxemis, Inc. Exoxemis is an early-stage biopharmaceutical research and development company focused on prevention and treatment of serious infections and the significant and growing problem of microbial drug resistance. The company’s myeloperoxidase (MPO) technology is a versatile platform that can be leveraged into multiple product areas, including medical, biodefense, industrial, veterinary, disinfectant, and agricultural applications.
In Hamburger’s most recent role at J & J, he was responsible for a cross-functional regulatory and drug development team and served as a global regulatory officer for the Oncology and Hematology division. His portfolio included the key biologic PROCRIT. Previously, he served in a similar role as the strategic and operational leader for the anti-cancer drug DOXIL. Prior to his tenure at J & J, Hamburger was Senior Regulatory Research Scientist, Oncology and US Regulatory Affairs for Eli Lilly and Company.
“Steve is an experienced regulatory strategist with a broad therapeutic background in the pharmaceutical industry including the areas of infectious diseases, cardiology and oncology,” noted Tom Callaway, MD, founder and president of Life Science Partner. “He’s a passionate and self-directed individual with a long track record of successful interactions with key global health authorities that will greatly benefit Exoxemis’ platform and opportunity.”
Hamburger received his Bachelor of Science degree in General Science and Biochemistry from the University of Iowa in Iowa City. He earned a Master of Science in Biology from Butler University in Indianapolis, Indiana and his PhD in Pharmacology and Toxicology from the Indiana University School of Medicine.